Researchers from the IIB Sant Pau, the CSIC, the CIBERCV and the Cardiology Service of the Sant Pau, publish in the journal Cardiovascular Research the mechanism by which patients with genetic variant on chromosome 4q25 present a higher incidence of atrial fibrillation. The study was carried out at the Hospital de Sant Pau in collaboration with the Polytechnic University of Catalonia and the University of Jaén.
The results of the study show that the propensity to atrial fibrillation is due to alterations in the regulation of intracellular calcium, as observed in myocytes isolated from patients carrying the variant on chromosome 4q25.
At present, genetic search technology has evolved enormously, reducing costs. This may allow the prevalence of genetic variants in the general population to be studied.
The relevance of the study is that it addresses the most frequent cardiac arrhythmia associated with high morbidity and the results justify a prospective study using drugs that modulate the release of intracellular calcium.
This publication opens the door to a prospective study with drugs that modulate the release of intracellular calcium to treat this arrhythmia. The authors of the article are evaluating which of the drugs with the ability to regulate intracellular calcium would be the best candidate to conduct the prospective clinical trial in the immediate future.
This is a scientific work that has recently been published in the journal Cardiovascular Research and is led by researchers from IIB Sant Pau, CSIC and CIBERCV. It has the collaboration of the Cardiology and Cardiac Surgery Services of San Pablo, the Polytechnic University of Catalonia and the University of Jaén.
To consult the study, click here
